|
Name: MAB-CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)
Type: Synthetic cannabinoid
AKA: MAB-CHMINACA, ADB-CHMINACA, synthetic cannabinoids
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
MAB-CHMINACA, a synthetic cannabinoid, was first synthesized in the early 2010s as part of research into new psychoactive substances. It was developed to interact with cannabinoid receptors, mimicking the effects of THC. MAB-CHMINACA gained popularity in the synthetic cannabis market, often found in 'herbal incense' products. Its potent effects and associated health risks led to regulatory actions aimed at controlling its distribution and addressing the rise of synthetic cannabinoids in recreational use.
|
|
V. Legal Information
MAB-CHMINACA is a synthetic cannabinoid with similar regulations to other cannabinoids. Globally, it is controlled under analog laws and UNODC guidelines due to its potential for abuse. In the U.S., it is considered a Schedule I substance under the Controlled Substances Act due to its analog status. The regulatory trend is towards expanding control measures to cover a broad range of synthetic cannabinoids to curb their misuse. [Source: UNODC].
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
MAB-CHMINACA is a synthetic cannabinoid with potent psychoactive effects. It acts as an upper, producing altered perception and euphoria. Short-term use can lead to intense psychological effects, while long-term use may result in dependency and health issues. Overdose risks include severe psychological distress and potential toxicity. Safe use is uncertain due to limited research. Recent studies focus on its effects and associated health risks.  |
|
VII. Psychological Effects
MAB-CHMINACA, a synthetic cannabinoid, affects CB1 and CB2 receptors, leading to significant euphoria, altered perception, and relaxation. Immediate effects include mood elevation and sensory distortions, lasting several hours. Long-term use may result in severe psychological effects, including paranoia and cognitive impairments. Research emphasizes its potency and risks of dependence and mental health issues.
 |
|
VIII. Culture
MAB-CHMINACA is a synthetic cannabinoid with no historical lore, emerging in the 21st century. Its use is associated with the recreational drug market and has raised concerns due to its health risks. Its cultural impact involves its role as a synthetic high and related safety issues. Proponents might discuss its effects, while opponents emphasize potential dangers and regulatory challenges. Its use is primarily recreational.
 |